6-mercaptopurine therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

6-Mercaptopurine (6-MP) and its parent drug azathioprine (AZA) are well-known for their immunosuppressive and lymphocytotoxic properties. [1, 2] These anti-metabolite drugs have been shown to suppress disease activity in up to 70% of children with IBD; and among these patients, 50% will achieve a clinical response after 4 months of continuous therapy. [3, 4] Although the overall risk of 6-MP induced toxicity is low, [5, 6] not all patients achieve disease remission despite presumed therapeutic drug dosing; thereby suggesting that inherent differences in either drug metabolism [7] or immune modulation [2] may influence clinical responsiveness to therapy. Herein, we will review the use of AZA and 6-MP in the management of pediatric patients with IBD. Furthermore, the application of pharmacogenomic and 6-MP metabolite testing will also be discussed based on an analysis of the literature. Several recommendations will also be provided on applying this technology into clinical practice.

Original languageEnglish (US)
Title of host publicationPediatric Inflammatory Bowel Disease
PublisherSpringer US
Pages371-378
Number of pages8
ISBN (Print)9780387734804
DOIs
StatePublished - 2008

Fingerprint

6-Mercaptopurine
Azathioprine
Pharmaceutical Preparations
Pharmacogenetics
Therapeutics
Immunosuppressive Agents
Parents
Pediatrics
Technology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cuffari, C. (2008). 6-mercaptopurine therapy. In Pediatric Inflammatory Bowel Disease (pp. 371-378). Springer US. https://doi.org/10.1007/978-0-387-73481-1_29

6-mercaptopurine therapy. / Cuffari, Carmelo.

Pediatric Inflammatory Bowel Disease. Springer US, 2008. p. 371-378.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cuffari, C 2008, 6-mercaptopurine therapy. in Pediatric Inflammatory Bowel Disease. Springer US, pp. 371-378. https://doi.org/10.1007/978-0-387-73481-1_29
Cuffari C. 6-mercaptopurine therapy. In Pediatric Inflammatory Bowel Disease. Springer US. 2008. p. 371-378 https://doi.org/10.1007/978-0-387-73481-1_29
Cuffari, Carmelo. / 6-mercaptopurine therapy. Pediatric Inflammatory Bowel Disease. Springer US, 2008. pp. 371-378
@inbook{80c0728782214922a08670783fbe5d36,
title = "6-mercaptopurine therapy",
abstract = "6-Mercaptopurine (6-MP) and its parent drug azathioprine (AZA) are well-known for their immunosuppressive and lymphocytotoxic properties. [1, 2] These anti-metabolite drugs have been shown to suppress disease activity in up to 70{\%} of children with IBD; and among these patients, 50{\%} will achieve a clinical response after 4 months of continuous therapy. [3, 4] Although the overall risk of 6-MP induced toxicity is low, [5, 6] not all patients achieve disease remission despite presumed therapeutic drug dosing; thereby suggesting that inherent differences in either drug metabolism [7] or immune modulation [2] may influence clinical responsiveness to therapy. Herein, we will review the use of AZA and 6-MP in the management of pediatric patients with IBD. Furthermore, the application of pharmacogenomic and 6-MP metabolite testing will also be discussed based on an analysis of the literature. Several recommendations will also be provided on applying this technology into clinical practice.",
author = "Carmelo Cuffari",
year = "2008",
doi = "10.1007/978-0-387-73481-1_29",
language = "English (US)",
isbn = "9780387734804",
pages = "371--378",
booktitle = "Pediatric Inflammatory Bowel Disease",
publisher = "Springer US",

}

TY - CHAP

T1 - 6-mercaptopurine therapy

AU - Cuffari, Carmelo

PY - 2008

Y1 - 2008

N2 - 6-Mercaptopurine (6-MP) and its parent drug azathioprine (AZA) are well-known for their immunosuppressive and lymphocytotoxic properties. [1, 2] These anti-metabolite drugs have been shown to suppress disease activity in up to 70% of children with IBD; and among these patients, 50% will achieve a clinical response after 4 months of continuous therapy. [3, 4] Although the overall risk of 6-MP induced toxicity is low, [5, 6] not all patients achieve disease remission despite presumed therapeutic drug dosing; thereby suggesting that inherent differences in either drug metabolism [7] or immune modulation [2] may influence clinical responsiveness to therapy. Herein, we will review the use of AZA and 6-MP in the management of pediatric patients with IBD. Furthermore, the application of pharmacogenomic and 6-MP metabolite testing will also be discussed based on an analysis of the literature. Several recommendations will also be provided on applying this technology into clinical practice.

AB - 6-Mercaptopurine (6-MP) and its parent drug azathioprine (AZA) are well-known for their immunosuppressive and lymphocytotoxic properties. [1, 2] These anti-metabolite drugs have been shown to suppress disease activity in up to 70% of children with IBD; and among these patients, 50% will achieve a clinical response after 4 months of continuous therapy. [3, 4] Although the overall risk of 6-MP induced toxicity is low, [5, 6] not all patients achieve disease remission despite presumed therapeutic drug dosing; thereby suggesting that inherent differences in either drug metabolism [7] or immune modulation [2] may influence clinical responsiveness to therapy. Herein, we will review the use of AZA and 6-MP in the management of pediatric patients with IBD. Furthermore, the application of pharmacogenomic and 6-MP metabolite testing will also be discussed based on an analysis of the literature. Several recommendations will also be provided on applying this technology into clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84889979205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889979205&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-73481-1_29

DO - 10.1007/978-0-387-73481-1_29

M3 - Chapter

AN - SCOPUS:84889979205

SN - 9780387734804

SP - 371

EP - 378

BT - Pediatric Inflammatory Bowel Disease

PB - Springer US

ER -